Literature DB >> 29563109

Non-incisional eyelid everting suture technique for treating lower lid epiblepharon.

Ji Won Seo1, Sunah Kang2, Chanjoo Ahn2, Bita Esmaeli3, Ho-Seok Sa2,3.   

Abstract

BACKGROUND: This study investigated surgical outcomes of full-thickness eyelid everting sutures for lower lid epiblepharon and influential factors leading to surgical failure.
METHODS: A retrospective review was conducted of patients with lower lid epiblepharon who underwent surgical correction using the full-thickness eyelid everting suture technique. Lower lid epiblepharon was assessed preoperatively using a morphological classification (class I-IV) according to the horizontal skin fold height and a functional classification (grade 0-3) according to the severity of keratopathy. Four stitches with 5-0 coated polyglactin 910 sutures per eyelid were made, and all procedures were conducted under local anaesthesia in an office-based setting. To assess surgical outcomes, we evaluated undercorrection at 1 month and surgical failure at 6 months after the procedure. Several factors affecting surgical failure were also investigated
RESULTS: Sixty-eight eyes of 41 patients were included. There were no eyes showing an undercorrection at 1 month. Keratopathy was significantly improved at 6 months postoperation (P<0.01). All patients showed good cosmesis without undesired creation of a lower lid crease and no significant complications. Sixty-one eyes (89.7%) showed surgical success. Three patients (7.3%) required additional incisional surgery due to recurring irritation. The rate of surgical failure was significantly different between the patient groups classified by preoperative severity of keratopathy (P=0.026) and lower lid horizontal skin fold height (P<0.001). Multiple logistic regression analysis revealed that the lower lid horizontal skin fold height was significantly correlated with surgical failure (OR 18.367, P=0.002).
CONCLUSION: Non-incisional eyelid everting sutures have utility for the correction of lower lid epiblepharon with advantages including its simplicity, being performed in office under local anaesthesia and minimal changes in appearance. We suggest mild to moderate epiblepharon with class I or II horizontal skin fold height and grade 1 or 2 keratopathy as the criteria for considering this suture procedure. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  epiblepharon, surgical treatment, Quickert suture

Mesh:

Substances:

Year:  2018        PMID: 29563109     DOI: 10.1136/bjophthalmol-2017-311635

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Reporting outcomes of hyaluronic gel filler as a treatment for epiblepharon.

Authors:  John C Bladen; Raman Malhotra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-22       Impact factor: 3.117

2.  Sex-specific difference in age distribution of congenital lower eyelid epiblepharon in a Japanese population.

Authors:  Ma Regina Paula Valencia; Yasuhiro Takahashi; Shunsuke Nakakura; Hirohiko Kakizaki
Journal:  Jpn J Ophthalmol       Date:  2019-07-08       Impact factor: 2.447

3.  Skin redraping for correction of lower eyelid epiblepharon combined with medial epicanthal fold: a retrospective analysis of 286 Asian children.

Authors:  Ninghua Liu; Aijuan He; Lan Gong; Nan Song; Dan Wu
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 3.775

4.  Surgical Treatment of Epiblepharon Effectively Alleviates Keratopathy but Not Astigmatism: A Case-Control Study Utilizing Vector Analysis in East Asian Children.

Authors:  Shang-Te Ma; Yao-Lin Liu; Ching-Ju Hsieh; Yo-Shen Chen; Tzu-Hsun Tsai
Journal:  J Ophthalmol       Date:  2020-12-05       Impact factor: 1.909

5.  High-frequency radio wave electrocautery in modified Hotz operations for epiblepharon correction.

Authors:  Hyunkyu Lee; Jimin Youn; Sehyun Baek
Journal:  BMC Ophthalmol       Date:  2021-12-10       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.